Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

Astellas terminates ASP-2314/ACR-16 license agreement with Neurosearch

March 4, 2009

Zonisamide reduces tremor scores in patients with essential tremor

March 4, 2009

Taisho scientists present new antidepressive NMU2 ligands

March 4, 2009

Intellect Neurosciences' AD candidate Oxigon reported to have copper-binding properties

March 4, 2009

Marinus presents successful results from phase II ganaxolone trial

March 3, 2009

Endo licenses axomadol and returns rights to Transdur-sufentanil

March 3, 2009

Astellas and XenoPort announce results from phase II ASP-8825/XP-13512 trial

March 3, 2009

AstraZeneca receives FDA complete response letter for Seroquel XR sNDA

March 2, 2009

Somaxon receives FDA complete response letter for Silenor

March 2, 2009

New venlafaxine prodrugs for depression imparted by Solvay

March 2, 2009

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 9, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...